Richard Dillon

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party

Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee

Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in <i>FLT3</i> -mutated AML

Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States

Molecular, clinical, and therapeutic determinants of outcome in <i>NPM1</i>-mutated AML

Postinduction molecular MRD identifies patients with <i>NPM1</i> AML who benefit from allogeneic transplant in first remission

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations

Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS

Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with <i>KMT2A</i> and <i>NPM1</i> Alterations

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)

Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia

Molecular MRD is strongly prognostic in patients with <i>NPM1</i>-mutated AML receiving venetoclax-based nonintensive therapy

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring <i>KMT2A</i> or <i>NPM1</i> Alterations

T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancy

Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS

Criteria for Diagnosis and Molecular Monitoring of <i>NPM1</i>-Mutated AML

Venetoclax–based low intensity therapy in molecular failure of <i>NPM1</i>-mutated AML

Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an <scp>ELN‐DAVID</scp> expert panel

Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts

Optimal Post-Remission Consolidation Therapy in Patients with AML

Unified classification and risk-stratification in Acute Myeloid Leukemia

Pretransplant <i>FLT3</i>-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features

Overlapping features of therapy-related and de novo <i>NPM1</i>-mutated AML

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia